Filing Flows › Organogenesis Holdings (ORGO) › Recalls, complaints & regulation
Organogenesis Holdings (ORGO): clinical trials
Organogenesis Holdings (ORGO) beyond its filings: 2 active clinical trials.
Organogenesis Holdings' latest quarter
Organogenesis Holdings, Q3 2026: revenue $45.5M (-70% year over year), operating margin -64.9%, net loss $29.6M, operating cash flow −$18.6M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Organogenesis Holdings have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.